Verve Therapeutics — Company Overview, News & Financial Data

Verve Therapeutics (NASDAQ:VERV) is a biotechnology company focused on revolutionizing the treatment of cardiovascular diseases through gene editing. With a robust pipeline of innovative gene-editing therapies, Verve's main objective is to develop treatments that can permanently reduce the risk of coronary heart disease, the world's leading cause of death, with a single dose. The company leverages precise gene editing technologies, like CRISPR, to target the underlying genetic causes of these diseases, aiming to provide enduring therapeutic solutions. By focusing on the most common genetic contributors to cardiovascular risk, Verve aspires to transform the approach to heart disease prevention, moving from chronic management to one-time, potentially curative treatments.